Clinical Trial Update: Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating ticagrelor versus placebo for reducing vaso-occlusive crises in sickle cell disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Sickle Cell Disease | Phase 3 | Status: WITHDRAWN